The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better manage their type 2 diabetes. Now, new research suggests Eli Lilly’s weight loss drug Zepbound (tirzepetide) may also support those with obstructive sleep apnea by increasing airflow and improving sleep quality.